• +1-646-491-9876
    • +91-20-67278686

    Search

    Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2017

    Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2017

    • Report Code ID: RW0001709491
    • Category Pharmaceuticals
    • No. of Pages 113
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2017, provides an overview of the Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline landscape.

    H3N2 infections are caused by variant H3N2 virus which is an influenza virus. Symptoms include cough, sore throat, runny or stuffy nose, chills, nausea, vomiting, and/or diarrhea. Risk factors include age, chronic medical conditions like asthma, diabetes, heart disease, weakened immune systems, and neurological or neurodevelopment conditions. Treatment includes antiviral medications and antibiotics.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 7, 5, 16 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I and Preclinical stages comprises 1, 1, 1 and 4 molecules, respectively.

    Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Influenza A Virus, H3N2 Subtype Infections - Overview
    Influenza A Virus, H3N2 Subtype Infections - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Influenza A Virus, H3N2 Subtype Infections - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Influenza A Virus, H3N2 Subtype Infections - Companies Involved in Therapeutics Development
    AbbVie Inc
    AIMM Therapeutics BV
    Aphios Corp
    BiondVax Pharmaceuticals Ltd
    Celltrion Inc
    FluGen Inc
    Glide Pharmaceutical Technologies Ltd
    ILiAD Biotechnologies LLC
    Inovio Pharmaceuticals Inc
    Johnson & Johnson
    Medicago Inc
    MedImmune LLC
    Mucosis BV
    NanoViricides Inc
    Novavax Inc
    OPKO Health Inc
    Protein Sciences Corp
    Sanofi Pasteur SA
    Sarepta Therapeutics Inc
    SK Chemicals Co Ltd
    Takeda Pharmaceutical Company Ltd
    VBI Vaccines Inc
    Visterra Inc
    Zydus Cadila Healthcare Ltd
    Influenza A Virus, H3N2 Subtype Infections - Drug Profiles
    APP-0205 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    APP-309 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Aspidasept - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AV-5075S - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AV-5080 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cetylpyridinium chloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CR-8020 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CR-8043 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CTP-27 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Fluad (quadrivalent) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FluGEM - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gamma-Flu - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strain A/H3N2] (monovalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strain A/H3N2] vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strain A/H3N2] vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strain A/H3N2] vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strain A/H3N2v] vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strain A/H3N2v] vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H1N1 + A/H3N2 + B] vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    JNJ-3872 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    M-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NBP-607 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NEO-8877 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NVINF-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NVINF-2 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Peptides for Influenza Infections - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pertussis [strain BPZE1] vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PNSIA-28 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    radavirsen - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    REDEE FLU - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for RSV and Influenza A Infections - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VIS-410 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Influenza A Virus, H3N2 Subtype Infections - Dormant Projects
    Influenza A Virus, H3N2 Subtype Infections - Discontinued Products
    Influenza A Virus, H3N2 Subtype Infections - Product Development Milestones
    Featured News & Press Releases
    Jan 12, 2017: Study Published in Vaccine Journal Indicates BiondVax's Universal Flu Vaccine Candidate May Cover Strains Which Don't Yet Exist
    Jun 23, 2016: AstraZeneca provides update on Flumist Quadrivalent Vaccine in the US for the 2016-17 influenza season
    Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100
    Oct 09, 2012: NanoViricides's Oral FluCide Drug Candidate Found To Be Superior To Oseltamivir In Reduction Of Virus Load And Lung Damage Pathology In Animal Models With H3N2 Influenza
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Influenza A Virus, H3N2 Subtype Infections - Pipeline by AbbVie Inc, H1 2017
    Influenza A Virus, H3N2 Subtype Infections - Pipeline by AIMM Therapeutics BV, H1 2017
    Influenza A Virus, H3N2 Subtype Infections - Pipeline by Aphios Corp, H1 2017
    Influenza A Virus, H3N2 Subtype Infections - Pipeline by BiondVax Pharmaceuticals Ltd, H1 2017
    Influenza A Virus, H3N2 Subtype Infections - Pipeline by Celltrion Inc, H1 2017
    Influenza A Virus, H3N2 Subtype Infections - Pipeline by FluGen Inc, H1 2017
    Influenza A Virus, H3N2 Subtype Infections - Pipeline by Glide Pharmaceutical Technologies Ltd, H1 2017
    Influenza A Virus, H3N2 Subtype Infections - Pipeline by ILiAD Biotechnologies LLC, H1 2017
    Influenza A Virus, H3N2 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
    Influenza A Virus, H3N2 Subtype Infections - Pipeline by Johnson & Johnson, H1 2017
    Influenza A Virus, H3N2 Subtype Infections - Pipeline by Medicago Inc, H1 2017
    Influenza A Virus, H3N2 Subtype Infections - Pipeline by MedImmune LLC, H1 2017
    Influenza A Virus, H3N2 Subtype Infections - Pipeline by Mucosis BV, H1 2017
    Influenza A Virus, H3N2 Subtype Infections - Pipeline by NanoViricides Inc, H1 2017
    Influenza A Virus, H3N2 Subtype Infections - Pipeline by Novavax Inc, H1 2017
    Influenza A Virus, H3N2 Subtype Infections - Pipeline by OPKO Health Inc, H1 2017
    Influenza A Virus, H3N2 Subtype Infections - Pipeline by Protein Sciences Corp, H1 2017
    Influenza A Virus, H3N2 Subtype Infections - Pipeline by Sanofi Pasteur SA, H1 2017
    Influenza A Virus, H3N2 Subtype Infections - Pipeline by Sarepta Therapeutics Inc, H1 2017
    Influenza A Virus, H3N2 Subtype Infections - Pipeline by SK Chemicals Co Ltd, H1 2017
    Influenza A Virus, H3N2 Subtype Infections - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
    Influenza A Virus, H3N2 Subtype Infections - Pipeline by VBI Vaccines Inc, H1 2017
    Influenza A Virus, H3N2 Subtype Infections - Pipeline by Visterra Inc, H1 2017
    Influenza A Virus, H3N2 Subtype Infections - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
    Influenza A Virus, H3N2 Subtype Infections - Dormant Projects, H1 2017
    Influenza A Virus, H3N2 Subtype Infections - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    AbbVie Inc
    AIMM Therapeutics BV
    Aphios Corp
    BiondVax Pharmaceuticals Ltd
    Celltrion Inc
    FluGen Inc
    Glide Pharmaceutical Technologies Ltd
    ILiAD Biotechnologies LLC
    Inovio Pharmaceuticals Inc
    Johnson & Johnson
    Medicago Inc
    MedImmune LLC
    Mucosis BV
    NanoViricides Inc
    Novavax Inc
    OPKO Health Inc
    Protein Sciences Corp
    Sanofi Pasteur SA
    Sarepta Therapeutics Inc
    SK Chemicals Co Ltd
    Takeda Pharmaceutical Company Ltd
    VBI Vaccines Inc
    Visterra Inc
    Zydus Cadila Healthcare Ltd

    Request for Sample

    Report Url https://www.reportsweb.com//influenza-a-virus-h3n2-subtype-infections-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//influenza-a-virus-h3n2-subtype-infections-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//influenza-a-virus-h3n2-subtype-infections-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments